Wistar Institute Appointed New CEO to Lead Research Lab
Ronny Drapkin will take over leadership at the Philadelphia biomedical research institution this November.
Updated on Oct. 6, 2026 in People
Live Poll
Do you trust local biomedical research institutions to successfully manage their leadership and long-term scientific mission?
The Wistar Institute has appointed Ronny Drapkin as its new chief executive officer. Drapkin will succeed Dario Altieri, who served as CEO for 11 years and announced his departure in early 2026.
Why it matters
The leadership change marks a significant transition for the University City-based research center as it balances ongoing growth and facility expansion. For operators, the move signals a continued focus on talent acquisition, as the institute has added six principal investigators this year.
The Wistar Institute reported $72 million in total revenue last year, supporting a team of 41 lead scientists. The organization recently hired six new investigators this year to support its research infrastructure.
The players
Ronny Drapkin
Incoming chief executive officer of the Wistar Institute who is transitioning his research laboratory from the University of Pennsylvania.
Dario Altieri
Outgoing chief executive officer who led the Wistar Institute for 11 years before announcing his departure.
Wistar Institute
A Philadelphia-based biomedical research organization located in University City that maintains a staff of 41 lead scientists.
The details
Ronny Drapkin will relocate his existing research laboratory from the University of Pennsylvania to the Wistar Institute’s headquarters. This move is part of a broader institutional push to integrate new academic talent into the institute's current operational framework. The transition follows a year of significant capital allocation, including a $30 million anonymous gift dedicated to the Advanced Therapeutics Center.
Timeline
Dario Altieri announced his plans to step down in January 2026.
Ronny Drapkin will officially begin his role as CEO on November 30, 2026.
Market Landscape
This transition marks the end of the 11-year tenure established by Dario Altieri. The shift follows a period of institutional expansion characterized by the addition of six new principal investigators and significant capital investment.
Operators in the biomedical and research sectors should monitor how the new leadership influences the institute's procurement and partnership strategies. Tracking the utilization of the $30 million gift for the Advanced Therapeutics Center will provide a signal for future vendor opportunities.
The takeaway
Leadership changes at major research institutions often precede shifts in facility investment and hiring capacity. Organizations should monitor the Wistar Institute’s project timelines in early 2027 to assess potential new demand for scientific equipment and specialized services.
Further reading
For more coverage on executive transitions in the region, visit the People section.
Source note: This article includes information reported by The Philadelphia Inquirer.
Live Poll
Do you trust local biomedical research institutions to successfully manage their leadership and long-term scientific mission?
